AVEO Oncology (NASDAQ: AVEO) today reported its third quarter 2013 financial results.
“We continue to execute on the strategy we outlined earlier this year, focusing our resources where the unique insights derived from our proprietary Human Response Platform™ will enable the potential development of therapies for biomarker-defined patient populations,” said Tuan Ha-Ngoc, president and chief executive officer of AVEO.
Help employers find you! Check out all the jobs and post your resume.
